Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Fundamental data now powered by FactSet with hourly updates!

BGNE | BeiGene Ltd ADR

Healthcare | Biotechnology | Cayman Islands | NASD

Index	-	P/E	-	EPS (ttm)	-16.67	Insider Own	0.86%	Shs Outstand	-	Perf Week	-9.11%
Market Cap	18.39B	Forward P/E	-	EPS next Y	-9.36	Insider Trans	-83.36%	Shs Float	96.01M	Perf Month	-4.53%
Income	-1732.46M	PEG	-	EPS next Q	-3.16	Inst Own	48.19%	Short Float / Ratio	1.73% / 7.20	Perf Quarter	5.44%
Sales	1.81B	P/S	10.15	EPS this Y	35.38%	Inst Trans	-0.43%	Short Interest	1.66M	Perf Half Y	-13.58%
Book/sh	-	P/B	-	EPS next Y	25.43%	ROA	-26.44%	Target Price	277.58	Perf Year	31.83%
Cash/sh	36.41	P/C	5.22	EPS next 5Y	26.82%	ROE	-38.07%	52W Range	124.46 - 280.62	Perf YTD	-13.67%
Dividend	-	P/FCF	-	EPS past 5Y	-65.40%	ROI	-42.97%	52W High	-32.34%	Beta	0.72
Dividend %	-	Quick Ratio	2.90	Sales past 5Y	74.50%	Gross Margin	78.68%	52W Low	52.56%	ATR	8.40
Employees	9000	Current Ratio	3.13	Sales Q/Q	74.27%	Oper. Margin	-88.19%	RSI (14)	42.75	Volatility	3.38% 3.29%
Optionable	Yes	Debt/Eq	0.18	EPS Q/Q	34.47%	Profit Margin	-95.67%	Rel Volume	0.36	Prev Close	190.58
Shortable	Yes	LT Debt/Eq	0.06	Earnings	Aug 02 BMO	Payout	-	Avg Volume	230.37K	Price	189.88
Recom	1.43	SMA20	-5.98%	SMA50	-5.17%	SMA200	-14.59%	Volume	34,253	Change	-0.37%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-12-23	Initiated	Macquarie	Outperform	$259
Aug-17-23	Initiated	Jefferies	Buy	$287
Jul-17-23	Initiated	Citigroup	Buy	$275
Jun-30-23	Downgrade	Bernstein	Outperform → Mkt Perform	$335 → $196
Jan-12-23	Initiated	Daiwa Securities	Buy	$308
Oct-13-22	Upgrade	SVB Leerink	Mkt Perform → Outperform	$177 → $200
Oct-13-22	Upgrade	Guggenheim	Neutral → Buy	$205
Aug-09-22	Resumed	JP Morgan	Overweight	$296
Mar-17-22	Downgrade	SVB Leerink	Outperform → Mkt Perform	$300 → $177
Feb-07-22	Initiated	Deutsche Bank	Buy
Oct-12-21	Initiated	Bernstein	Outperform	$431
Oct-06-21	Upgrade	CLSA	Underperform → Buy
Mar-08-21	Initiated	China Renaissance	Buy
Mar-01-21	Downgrade	CLSA	Outperform → Underperform	$330 → $321
Nov-09-20	Downgrade	Ladenburg Thalmann	Buy → Neutral
Nov-06-20	Downgrade	Piper Sandler	Neutral → Underweight	$175 → $185
Nov-06-20	Downgrade	Maxim Group	Buy → Hold
Jul-10-20	Downgrade	CLSA	Buy → Outperform
Mar-13-20	Upgrade	Macquarie	Underperform → Neutral
Feb-18-20	Resumed	Goldman	Buy

Show Previous Ratings

Sep-19-23 06:22AM	UPDATE 3-BeiGene to go solo with cancer drug after Novartis deal termination (Reuters)
06:15AM	BeiGene Announces Positive Regulatory Updates in Europe and the U.S. After Recently Regaining Global Rights for TEVIMBRA® (Business Wire)
06:10AM	BeiGene regains rights for cancer drug after Novartis deal termination (Reuters)
06:00AM	BeiGene Strengthens Global Portfolio and Regains Full Rights from Novartis for Anti-PD-1 Antibody TEVIMBRA® (tislelizumab) (Business Wire)
Sep-12-23 09:53AM	CVS upgraded, RTX downgraded: Wall Street's top analyst calls (The Fly)
07:00AM	Loading…
Aug-31-23 07:00AM	BeiGene to Present at the Morgan Stanley 21st Annual Global Healthcare Conference (Business Wire)
Aug-17-23 09:39AM	Adobe upgraded, BorgWarner downgraded: Wall Street's top analyst calls (The Fly)
Aug-02-23 06:00AM	BeiGene Accelerates Global Momentum with Strong Second Quarter 2023 Financial Results (Business Wire) -8.12%
Jul-21-23 07:50AM	BeiGene Announces Positive CHMP Opinion for Tislelizumab as a Treatment for Advanced or Metastatic ESCC (Business Wire)
Jul-14-23 09:58AM	Ray Dalios China Stocks (Insider Monkey)
Jul-13-23 08:12AM	Is There An Opportunity With BeiGene, Ltd.'s (NASDAQ:BGNE) 39% Undervaluation? (Simply Wall St.)
Jul-12-23 07:00AM	BeiGene Announces FDA Acceptance of sNDA for Fifth BRUKINSA® Indication (Business Wire)
Jul-10-23 07:00AM	BeiGene and DualityBio Announce Partnership to Advance Differentiated Antibody Drug Conjugate (ADC) Therapy for Solid Tumors (Business Wire)
Jul-07-23 07:00AM	BeiGene to Host Investor Research and Development Day in Person and via Webcast on July 18, 2023 (Business Wire)
Jun-15-23 01:20PM	AbbVie Says BeiGene's Flagship Blood Cancer Drug Infringes Imbruvica Patent (Benzinga)
08:37AM	Loading…
08:37AM	BeiGene to Vigorously Defend Patent Infringement Allegations by Pharmacyclics (Business Wire)
03:00AM	BeiGene Highlights Significant BRUKINSA® (zanubrutinib) Data at the 17th International Conference on Malignant Lymphoma (Business Wire)
Jun-09-23 03:01AM	BeiGene Highlights Promising Data from Blood Cancer Portfolio and Pipeline at the European Hematology Association Hybrid Congress (Business Wire)
May-30-23 07:00AM	Health Canada Approves(PR) BRUKINSA® (zanubrutinib) for the Treatment of Chronic Lymphocytic Leukemia (CLL), the Most Common Leukemia in Adults (CNW Group)
07:00AM	BRUKINSA® Approved in Canada for the Treatment of Chronic Lymphocytic Leukemia (Business Wire)
May-25-23 05:05PM	BeiGene Presentations at the 2023 ASCO Annual Meeting Reinforce Promise Across Oncology Portfolio (Business Wire)
02:45PM	Institutional investors are BeiGene, Ltd.'s (NASDAQ:BGNE) biggest bettors and were rewarded after last week's US$813m market cap gain (Simply Wall St.)
May-24-23 07:00AM	BeiGene to Present at Upcoming Investor Conferences (Business Wire)
May-17-23 07:00AM	The Max Foundation, BeiGene, and the BeiGene Foundation Announce Collaboration to Advance Health Equity by Providing Access to BRUKINSA® for the Treatment of Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries (Business Wire)
May-11-23 07:02AM	Daily Vickers Top Buyers & Sellers for 05/11/2023 (Argus Research)
May-09-23 09:29AM	12 Best Fast Growth Stocks to Buy Now (Insider Monkey)
May-06-23 08:00AM	BeiGene Receives New Approvals for BRUKINSA® (zanubrutinib) in China (Business Wire)
May-05-23 06:01AM	BeiGene First Quarter 2023 Earnings: EPS Beats Expectations (Simply Wall St.)
May-04-23 07:00AM	BeiGene Reports First Quarter 2023 Financial Results and Corporate Developments (Business Wire)
Apr-28-23 01:39PM	12 Best Fast Growth Stocks to Buy Now (Insider Monkey)
10:27AM	Loading…
Apr-26-23 10:27AM	BeiGene to Highlight Broad Oncology Portfolio at the 2023 ASCO Annual Meeting (Business Wire)
Apr-25-23 08:45AM	3 Top Biotech Stocks Defying the Bear Market (Motley Fool)
07:00AM	BeiGene Announces Goals Focused on Sustainable Growth and Workforce Diversity in New ESG Report (Business Wire)
Apr-20-23 01:50PM	BeiGene's Tislelizumab/Chemo Combo Hits Primary Goal In Gastric Cancer Study (Benzinga)
07:00AM	BeiGene Announces Positive Phase 3 Tislelizumab Trial in Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (Business Wire)
Apr-19-23 07:22PM	7 Biotech Stocks That Could Cure Your Portfolio Woes (InvestorPlace)
Apr-17-23 02:32PM	SpringWorks and BeiGene Present Clinical Data on Lifirafenib, in combination with Mirdametinib, in Patients with Advanced or Refractory Solid Tumors with MAPK Pathway Aberrations at the American Association for Cancer Research Annual Meeting 2023 (GlobeNewswire)
02:32PM	BeiGene and SpringWorks Present Clinical Data on Lifirafenib, in Combination with Mirdametinib, in Patients with Advanced or Refractory Solid Tumors with MAPK Pathway Aberrations at the American Association for Cancer Research Annual Meeting 2023 (Business Wire)
02:30PM	MapKure, SpringWorks and BeiGene Present Clinical Data on BGB-3245, a Selective Next-Generation B-RAF Inhibitor, in Adult Patients with Advanced or Refractory Solid Tumors at the American Association for Cancer Research Annual Meeting 2023 (GlobeNewswire)
02:30PM	MapKure, BeiGene and SpringWorks Present Clinical Data on BGB-3245, a Selective Next-Generation B-RAF Inhibitor, in Adult Patients with Advanced or Refractory Solid Tumors at the American Association for Cancer Research Annual Meeting 2023 (Business Wire)
08:41AM	BeiGene, Ltd.'s (NASDAQ:BGNE) Business Is Yet to Catch Up With Its Share Price (Simply Wall St.)
Apr-14-23 02:45PM	The FDA Is Resuming Drug Lab Inspections in China. These Biotechs Could Benefit. (Barrons.com)
Apr-13-23 12:02PM	Stock Market Near Highs Ahead Of Bank News; Oprah Winfrey Stock Up 82% On 883% Growth Forecast (Investor's Business Daily)
10:45AM	Recession Fears Grow Despite Stock Market Bounce; Oil, Gold On Fire While Delta Traps Bulls (Investor's Business Daily)
07:00AM	BeiGene Expands Presence in Latin America With Opening of Brazil Office (Business Wire)
Apr-10-23 03:07AM	BeiGene, Ltd. (BGNE) Surges 12.5%: Is This an Indication of Further Gains? (Zacks)
Apr-06-23 05:24PM	Why BeiGene Stock Jumped Thursday (Motley Fool) +12.48%
Mar-30-23 07:00AM	BeiGene Appoints Julius Pryor III as First Global Head of Diversity and Health Equity (Business Wire)
Mar-27-23 06:25AM	Investing in BeiGene (NASDAQ:BGNE) three years ago would have delivered you a 75% gain (Simply Wall St.)
Mar-25-23 02:53PM	J.P. Morgan Analysts Say These 2 Stocks Are Their Top Picks for 2023 (TipRanks)
Mar-21-23 07:00AM	BeiGene Enters New Phase to Expand US Manufacturing and R&D Footprint in New Jersey (Business Wire)
Mar-17-23 12:26PM	BeiGene Will Not Go Forward With Licensing Pact For Leap Therapeutics' Lead Cancer Candidate (Benzinga)
Mar-16-23 12:06PM	Prelude (PRLD) Collaborates With BeiGene for Oncology Candidate (Zacks)
Mar-13-23 05:30AM	Tencent, Alibaba, AIA fuel Hong Kong market rally while BeiGene erases loss amid Silicon Valley Bank fallout (South China Morning Post)
05:30AM	HKMA monitoring Silicon Valley Bank fallout as Hong Kong-listed firms' exposure reaches US$217 million (South China Morning Post)
Mar-08-23 12:36PM	Q4 2022 Zymeworks Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-28-23 11:54AM	11 Most Promising Cancer Stocks According to Analysts (Insider Monkey)
09:35AM	Down -15.66% in 4 Weeks, Here's Why You Should You Buy the Dip in BeiGene, Ltd. (BGNE) (Zacks)
Feb-27-23 09:35AM	Here's Why BeiGene, Ltd. (BGNE) is Poised for a Turnaround After Losing -17.02% in 4 Weeks (Zacks)
07:00AM	BeiGene Reports Fourth Quarter and Full Year 2022 Financial Results (Business Wire)
Feb-26-23 08:04AM	12 High Growth Healthcare Stocks to Buy (Insider Monkey)
Feb-24-23 07:00AM	BeiGene to Present at Cowens 43rd Annual Healthcare Conference (Business Wire)
07:00AM	BeiGene Receives 10th Approval for PD-1 Inhibitor Tislelizumab in China (Business Wire)
Feb-23-23 08:34AM	Is a Surprise Coming for BeiGene (BGNE) This Earnings Season? (Zacks)
Feb-22-23 09:35AM	Down -14.15% in 4 Weeks, Here's Why BeiGene, Ltd. (BGNE) Looks Ripe for a Turnaround (Zacks)
Feb-15-23 09:40AM	Is Apexigen, Inc. (APGN) Stock Outpacing Its Medical Peers This Year? (Zacks)
Feb-06-23 06:37AM	Quebec becomes first province to cover PrBRUKINSA® (zanubrutinib) for the Treatment of Waldenström's macroglobulinemia (CNW Group)
Feb-03-23 07:00AM	New Talk About It Resources Aim to Accelerate Integration of Mental Health into Quality Cancer Care (Business Wire)
05:53AM	Is There An Opportunity With BeiGene, Ltd.'s (NASDAQ:BGNE) 40% Undervaluation? (Simply Wall St.)
Feb-01-23 07:00AM	BeiGene to Present at Upcoming Investor Conferences (Business Wire)
Jan-20-23 01:00PM	Jazz (JAZZ) Gastric Cancer Study Shows Improved Overall Survival (Zacks)
06:22AM	FDA Approves BeiGene's Brukinsa For Chronic Lymphocytic Leukemia (Benzinga)
Jan-19-23 05:03PM	BRUKINSA® Approved in the U.S. for Chronic Lymphocytic Leukemia (Business Wire)
07:00AM	BRUKINSA® (zanubrutinib) Receives Marketing Authorization for Chronic Lymphocytic Leukemia (CLL) and Marginal Zone Lymphoma (MZL) in Great Britain by MHRA (Business Wire)
Jan-18-23 05:32PM	One of the greatest cancer drugs ever has suddenly lost its edge. This is why it was vulnerable. (MarketWatch)
08:27AM	BeiGene Announces Expansion of Coverage on Chinas National Reimbursement Drug List (Business Wire)
Jan-17-23 05:00PM	BeiGene Presents New Research from Tislelizumab Global Development Program at 2023 ASCO Gastrointestinal Cancers Symposium (Business Wire)
Jan-16-23 08:50AM	What Makes BeiGene, Ltd. (BGNE) a Good Fit for 'Trend Investing' (Zacks)
Jan-04-23 07:07AM	BeiGene to Present at the J.P. Morgan 41st Annual Healthcare Conference (Business Wire) +7.18%
Dec-30-22 09:00AM	BeiGene Announces Acceptance of 12th Regulatory Submission in China for PD-1 Inhibitor Tislelizumab (Business Wire)
Dec-13-22 10:00AM	BeiGenes BRUKINSA® (zanubrutinib) Demonstrated Superior Progression-Free Survival Over IMBRUVICA® (ibrutinib) in Chronic Lymphocytic Leukemia in Late-Breaker at ASH (Business Wire)
Dec-09-22 07:00AM	BeiGene Calls for Greater Integration of Mental Health in Cancer Care After New Survey Reveals Gaps/Barriers for Patients and Survivors (Business Wire)
Dec-08-22 03:01PM	BeiGene Stock Shows Market Leadership With Jump To 82 RS Rating (Investor's Business Daily)
02:10PM	Phanes Therapeutics Announces Clinical Supply Agreement with BeiGene to Evaluate PT199 in combination with Tislelizumab (PR Newswire)
Dec-01-22 08:12AM	Why Shares of BeiGene Were Up Wednesday (Motley Fool)
Nov-27-22 08:39AM	In the wake of BeiGene, Ltd.'s (NASDAQ:BGNE) latest US$2.9b market cap drop, institutional owners may be forced to take severe actions (Simply Wall St.)
Nov-22-22 08:30AM	BeiGene to Present Final PFS Results from ALPINE Trial Demonstrating Superior PFS for BRUKINSA® Versus IMBRUVICA® in Late-Breaking Oral Session at ASH 2022 (Business Wire) -9.30%
Nov-17-22 07:00AM	BeiGene Receives European Commission Approval for BRUKINSA® (zanubrutinib) for the Treatment of Adults with Chronic Lymphocytic Leukemia (CLL) (Business Wire)
Nov-15-22 07:00AM	BeiGene Launches Talk About It Program to Elevate the Importance of Addressing Mental Health during Cancer Care (Business Wire)
Nov-10-22 07:00AM	BeiGene Announces Brazil Approvals for BRUKINSA® As a Treatment for Rare Blood Cancers (Business Wire) +7.13%
Nov-09-22 07:00AM	BeiGene Reports Third Quarter 2022 Financial Results (Business Wire) -6.82%
Nov-04-22 07:00AM	BeiGene to Present at Upcoming Investor Conferences (Business Wire)
Nov-03-22 09:15AM	Is This Chinese Pharmaceutical Stock Worth the Risk? (Motley Fool)
09:00AM	BeiGene to Present Dynamic View of Development Programs for Hematologic Malignancies at 64th ASH Meeting (Business Wire)
Nov-02-22 07:00AM	BeiGene Receives European Commission Approval for BRUKINSA® (zanubrutinib) for the Treatment of Adults with Marginal Zone Lymphoma (Business Wire) +5.31%
Oct-26-22 07:00AM	BeiGene Expands Reach of its Innovative BTK Inhibitor with Recent Regulatory Approvals in Latin America (Business Wire) +6.27%
Oct-17-22 12:31PM	Investors ignore increasing losses at BeiGene (NASDAQ:BGNE) as stock jumps 16% this past week (Simply Wall St.) +7.05%
Oct-14-22 10:26AM	European Heath Agency's Committee Backs Approving BeiGene's Brukinsa In Leukemia Setting (Benzinga)
06:30AM	BeiGene Receives Positive CHMP Opinion for BRUKINSA® (zanubrutinib) for the Treatment of Adults With CLL (Business Wire)
Oct-13-22 11:08AM	BeiGene, Ltd. (BGNE) Soars 20.6%: Is Further Upside Left in the Stock? (Zacks)

BeiGene Ltd. is a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Lee Chan Henry	SVP, General Counsel	Jul 31	Sale	216.26	791	171,059	0	Aug 02 05:10 PM
Wang Julia Aijun	Chief Financial Officer	Jul 03	Sale	179.55	472	84,747	0	Jul 06 05:02 PM
Wu Xiaobin	President, COO & GM China	Jun 26	Sale	182.37	1,495	272,636	0	Jun 27 05:20 PM
Wang Lai	Global Head of R&D	Jun 26	Sale	181.92	1,108	201,567	0	Jun 27 05:24 PM
Wang Julia Aijun	Chief Financial Officer	Jun 23	Sale	182.85	840	153,594	0	Jun 27 05:22 PM
Sanders Corazon (Corsee) D.	Director	Jun 23	Sale	182.32	578	105,381	0	Jun 27 05:21 PM
Wang Lai	Global Head of R&D	Jun 20	Sale	192.42	1,325	254,955	0	Jun 20 06:53 PM
HHLR ADVISORS, LTD.	10% Owner	Jun 14	Sale	207.72	273,728	56,857,986	142,888,241	Jun 15 07:25 PM
HHLR ADVISORS, LTD.	10% Owner	Jun 13	Sale	183.31	924,400	169,448,353	143,161,969	Jun 15 07:25 PM
HHLR ADVISORS, LTD.	10% Owner	Jun 12	Sale	195.21	1,250,212	244,057,178	144,086,369	Jun 12 09:57 PM
HHLR ADVISORS, LTD.	10% Owner	Jun 09	Sale	182.89	542,652	99,244,890	145,336,581	Jun 12 09:57 PM
HHLR ADVISORS, LTD.	10% Owner	Jun 08	Sale	218.14	1,163,825	253,881,790	145,879,233	Jun 12 09:57 PM
Wu Xiaobin	President, COO & GM China	Jun 07	Sale	224.73	3,291	739,599	0	Jun 09 05:44 PM
Wang Lai	Global Head of R&D	Jun 07	Sale	224.74	462	103,828	0	Jun 09 05:46 PM
Wu Xiaobin	President, COO & GM China	May 08	Sale	253.72	7,000	1,776,037	0	May 10 04:44 PM
Wang Xiaodong	Chair, Scientific Advisory Brd	Mar 08	Option Exercise	0.13	67,635	8,793	67,635	Mar 10 06:48 PM
Wang Xiaodong	Chair, Scientific Advisory Brd	Mar 08	Sale	226.03	67,635	15,287,339	0	Mar 10 06:48 PM
Wang Julia Aijun	Chief Financial Officer	Mar 01	Sale	240.21	343	82,392	0	Mar 03 05:00 PM
Wang Xiaodong	Chair, Scientific Advisory Brd	Jan 12	Sale	260.52	5,000	1,302,585	0	Jan 17 05:13 PM
Wang Xiaodong	Chair, Scientific Advisory Brd	Jan 11	Sale	252.66	2,500	631,647	0	Jan 11 04:50 PM
OYLER JOHN	Chief Executive Officer	Jan 10	Sale	248.51	13,594	3,378,292	0	Jan 12 04:52 PM
OYLER JOHN	Chief Executive Officer	Jan 10	Sale	248.52	6,797	1,689,157	0	Jan 12 04:52 PM
Wang Xiaodong	Chair, Scientific Advisory Brd	Jan 10	Sale	250.09	1,600	400,152	0	Jan 11 04:50 PM
Wang Xiaodong	Chair, Scientific Advisory Brd	Jan 09	Sale	250.00	900	225,000	0	Jan 11 04:50 PM
OYLER JOHN	Chief Executive Officer	Dec 29	Sale	224.46	3,434	770,798	0	Dec 29 06:24 PM
OYLER JOHN	Chief Executive Officer	Dec 29	Sale	224.46	1,716	385,174	0	Dec 29 06:24 PM
OYLER JOHN	Chief Executive Officer	Dec 28	Sale	224.73	733	164,724	0	Dec 29 06:24 PM
OYLER JOHN	Chief Executive Officer	Dec 28	Sale	224.73	367	82,474	0	Dec 29 06:24 PM
OYLER JOHN	Chief Executive Officer	Dec 27	Sale	224.29	2,239	502,193	0	Dec 29 06:24 PM
OYLER JOHN	Chief Executive Officer	Dec 27	Sale	224.29	1,120	251,209	0	Dec 29 06:24 PM
Wang Xiaodong	Chair, Scientific Advisory Brd	Dec 13	Sale	211.33	3,013	636,723	0	Dec 15 05:04 PM
OYLER JOHN	Chief Executive Officer	Nov 15	Sale	206.84	25,000	5,171,105	0	Nov 17 05:10 PM
OYLER JOHN	Chief Executive Officer	Nov 15	Sale	206.82	4,928	1,019,229	0	Nov 17 05:10 PM
Wang Xiaodong	Chair, Scientific Advisory Brd	Nov 15	Sale	210.14	1,987	417,541	0	Nov 17 05:13 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

BGNE | BeiGene Ltd ADR

Upgrade your FINVIZ experience